BWA
RCKT icon

Basecamp Wealth Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Basecamp Wealth Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$482 Sell
141
-86
-38% -$286 ﹤0.01% 1639
2026
Q1 		$813 Buy
227
+122
+116% +$485 ﹤0.01% 1611
2025
Q4 		$369 Buy
+105
New +$359 ﹤0.01% 1668

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Basecamp Wealth Advisors's RCKT Position: Q2 2026 in Review

Basecamp Wealth Advisors reduced its Rocket Pharmaceuticals (RCKT) stake by 38% in Q2 2026, selling an estimated $286 and leaving 141 shares worth $482. The position accounts for ﹤0.01% of the portfolio, ranked #1639.

Basecamp Wealth Advisors first reported a position in RCKT in Q4 2025 and has held it in 3 quarters since. The position peaked at $813 in Q1 2026. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Basecamp Wealth Advisors held 141 shares of Rocket Pharmaceuticals worth $482 as of Q2 2026.
  • Basecamp Wealth Advisors sold 86 Rocket Pharmaceuticals shares in Q2 2026, an estimated $286.
  • Rocket Pharmaceuticals made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1639 holding.
  • Basecamp Wealth Advisors first reported a position in Rocket Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Basecamp Wealth Advisors's Rocket Pharmaceuticals position peaked at $813 in Q1 2026.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.